A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Naive or Have Received Interferon Based Therapy
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Telaprevir (Primary) ; Interferon beta; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 01 Feb 2018 Results published in the Hepatology Research.
- 23 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 09 Jun 2015 Planned End Date changed from 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov